CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
小分子调控开关实现患者体内 CAR-T 细胞的功能控制
英文原题：Small molecule-regulated switches to provide functional control of CAR T cells within the patient.
查看英文原题
Small molecule-regulated switches to provide functional control of CAR T cells within the patient.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
亟需开发先进的开关系统。
中文摘要
CAR-T 细胞在部分血液恶性肿瘤中产生了令人瞩目的临床缓解，但这些工程化免疫细胞是给药后难以控制的“活药物”。本文讨论可在患者体内调控CAR-T 功能的小分子开关系统，以及这类系统可能克服的领域关键障碍。作者认为亟需开发先进开关系统；一旦可用，有望为未来一代CAR-T 疗法开辟新方向。
展开英文摘要原文
INTRODUCTION: CAR T cells have generated great excitement due to their remarkable clinical response rates in selected hematologic malignancies.
However, these engineered immune cells are living drugs which are hard to control after administration. AREAS COVERED: We discuss small molecule-regulated switch systems which can potentially be used to control CAR T cell function within the patient, as well as the most important obstacles in the CAR T cell field, which might be overcome with those switch systems. EXPERT OPINION: There is an urgent need to develop advanced switch systems. Once available, we expect that they will open up new avenues for future CAR T cell generations.
论文信息
- 作者
- Zajc CU、Sylvander E、Lehner M、Traxlmayr MW
- 单位
- Department of Chemistry, Institute of Biochemistry, BOKU University, Vienna, Austria.Austria
- 文献类型
- 综述
- 期刊
- Expert opinion on biological therapy2024 Jun
- 原文标识
- PubMed 38943466 · DOI 10.1080/14712598.2024.2371034